rxstatShortages › Rabeprazole

Rabeprazole (Pariet, Enteric-Coated) shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 28, 2026

Some Rabeprazole products are in shortage in Canada (5 of 21 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Aug 14, 2026.

A proton pump inhibitor used to reduce stomach acid in conditions such as acid reflux and ulcers.

Products affected
5 / 21
In shortage since
Nov 14, 2021
Est. full return
Aug 14, 2026
Reports on file
74
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Book a pharmacist appointment
Need your prescription switched?
If your product stays unavailable, an online doctor can assess your situation and prescribe an alternative.
See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Active shortage
SANDOZ RABEPRAZOLE
20MG · TABLET (ENTERIC-COATED) · SANDOZ CANADA INCORPORATED
DIN 02314185 · since Jul 27, 2026, est. end Aug 14, 2026 · Requirements related to complying with good manufacturing practices.
Active shortage
JAMP RABEPRAZOLE
20MG · TABLET (DELAYED-RELEASE) · JAMP PHARMA CORPORATION
DIN 02415291 · since Aug 7, 2025, est. end Jun 30, 2026 · Disruption of the manufacture of the drug.
Active shortage
JAMP RABEPRAZOLE
10MG · TABLET (DELAYED-RELEASE) · JAMP PHARMA CORPORATION
DIN 02415283 · since Aug 7, 2025, est. end Jun 30, 2026 · Disruption of the manufacture of the drug.
Active shortage
PMS-RABEPRAZOLE EC
20MG · TABLET (ENTERIC-COATED) · PHARMASCIENCE INC
DIN 02310813 · since Aug 17, 2022, no end estimate · Disruption of the manufacture of the drug.
Active shortage
PMS-RABEPRAZOLE EC
10MG · TABLET (ENTERIC-COATED) · PHARMASCIENCE INC
DIN 02310805 · since Nov 14, 2021, no end estimate · Disruption of the manufacture of the drug.
Anticipated
SANDOZ RABEPRAZOLE
20MG · TABLET (ENTERIC-COATED) · SANDOZ CANADA INCORPORATED
DIN 02314185 · Disruption of the manufacture of the drug.
Anticipated
SANDOZ RABEPRAZOLE
20MG · TABLET (ENTERIC-COATED) · SANDOZ CANADA INCORPORATED
DIN 02314185 · Disruption of the manufacture of the drug.
Resolved
SANDOZ RABEPRAZOLE
20MG · TABLET (ENTERIC-COATED) · SANDOZ CANADA INCORPORATED
DIN 02314185 · ended May 4, 2026 · Delay in shipping of the drug.
Resolved
SANDOZ RABEPRAZOLE
20MG · TABLET (ENTERIC-COATED) · SANDOZ CANADA INCORPORATED
DIN 02314185 · ended Mar 30, 2026 · Disruption of the manufacture of the drug.
Resolved
JAMP RABEPRAZOLE
20MG · TABLET (DELAYED-RELEASE) · JAMP PHARMA CORPORATION
DIN 02415291 · ended Jul 31, 2025 · Disruption of the manufacture of the drug.
Resolved
JAMP RABEPRAZOLE
20MG · TABLET (DELAYED-RELEASE) · JAMP PHARMA CORPORATION
DIN 02415291 · ended Jul 31, 2025 · Disruption of the manufacture of the drug.
Resolved
JAMP RABEPRAZOLE
10MG · TABLET (DELAYED-RELEASE) · JAMP PHARMA CORPORATION
DIN 02415283 · ended Jul 31, 2025 · Disruption of the manufacture of the drug.

Showing 12 of 60 reports. All reports are on file with Health Canada.

What's happening

Rabeprazole is currently affected by 5 active shortage reports filed with Health Canada by SANDOZ CANADA INCORPORATED, JAMP PHARMA CORPORATION, PHARMASCIENCE INC.

The reported causes are: requirements related to complying with good manufacturing practices; disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Rabeprazole is classified under “DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)” (ATC A02BC).

Recent changes

Common questions

What is Rabeprazole used for?

A proton pump inhibitor used to reduce stomach acid in conditions such as acid reflux and ulcers.

When will Rabeprazole be back in stock in Canada?

The latest manufacturer estimate is Aug 14, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Rabeprazole in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (drugs for peptic ulcer and gastroesophageal reflux disease (gerd))

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.